GILL JOHN 4

What Happened John Gill, a director of Altimmune, purchased 9,200 shares in an open-market/private purchase reported on April 6, 2026. The reported weighted-average price was $3.41 per share, for a total purchase value of approximately $31,350. This is a purchase (insider buy), which investors often view as a sign of confidence by the insider, though it does not prove future performance.

Key Details

• Transaction date: 2026-04-06 (reported same day; filing appears timely)
• Transaction type/code: Open market or private purchase (Code P)
• Shares purchased: 9,200
• Price: weighted average $3.41; actual trade prices ranged from $3.4050 to $3.4080 (footnote)
• Total consideration: ~$31,350
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnote: Reporting person will provide, upon request, the number of shares bought at each individual price within the stated range

Context

• Purchases by directors are factual signals of personal investment but are not definitive predictions of company performance.
• The filing discloses a weighted-average price and multiple underlying transactions; the reporting person offers to supply a per-trade breakdown to investors or SEC staff if requested.